Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Summary
NOTE: This trial is currently enrolling in Part I.
The purpose of this phase II study is to evaluate the safety and efficacy of palbociclib in combination with gedatolisib in patients with advanced solid tumors, including pancreatic cancer.
General Information
NCT#: NCT03065062
Study ID: 16-499
Trial Phase: Phase I
Trial Sponsor: Pfizer, Dana-Farber Cancer Institute
Therapies Used in This Trial: Gedatolisib, Palbociclib